1. Melton LJ 3rd. The epidemiology of primary hyperparathyroidism in North America. J Bone Miner Res. 2002. 17:N12–N17.
2. Wynne AG, van Heerden J, Carney JA, Fitzpatrick LA. Parathyroid carcinoma: clinical and pathologic features in 43 patients. Medicine (Baltimore). 1992. 71:197–205.
3. Shane E. Clinical review 122: Parathyroid carcinoma. J Clin Endocrinol Metab. 2001. 86:485–493.
4. Howell VM, Haven CJ, Kahnoski K, Khoo SK, Petillo D, Chen J, Fleuren GJ, Robinson BG, Delbridge LW, Philips J, Nelson AE, Krause U, Hammje K, Dralle H, Hoang-Vu C, Gimm O, Marsh DJ, Morreau H, Teh BT. HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours. J Med Genet. 2003. 40:657–663.
5. Shattuck TM, Välimäki S, Obara T, Gaz RD, Clark OH, Shoback D, Wierman ME, Tojo K, Robbins CM, Carpten JD, Farnebo LO, Larsson C, Arnold A. Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med. 2003. 349:1722–1729.
6. Koea JB, Shaw JH. Parathyroid cancer: biology and management. Surg Oncol. 1999. 8:155–165.
7. Savli H, Sevinc A, Sari R, Ozen S, Buyukberber S, Ertas E. Occult parathyroid carcinoma in a patient with papillary thyroid carcinoma and Hashimoto's thyroiditis. J Endocrinol Invest. 2001. 24:42–44.
8. Schoretsanitis G, Melissas J, Kafousi M, Karkavitsas N, Tsiftsis DD. Synchronous parathyroid and papillary thyroid carcinoma: a case report. Am J Otolaryngol. 2002. 23:382–385.
9. Chang HS, Yoon JH, Chung WY, Park CS. Coexistence of parathyroid and papillary thyroid carcinoma. J Korean Surg Soc. 2004. 66:147–152.
10. Burmeister LA, Sandberg M, Carty SE, Watson CG. Thyroid carcinoma found at parathyroidectomy: association with primary, secondary, and tertiary hyperparathyroidism. Cancer. 1997. 79:1611–1616.
11. Leitha T, Staudenherz A. Concomitant hyperparathyroidism and nonmedullary thyroid cancer, with a review of the literature. Clin Nucl Med. 2003. 28:113–117.
12. Pomares FJ, Canas R, Rodriguez JM, Hernandez AM, Parrilla P, Tebar FJ. Differences between sporadic and multiple endocrine neoplasia type 2A phaeochromocytoma. Clin Endocrinol(Oxf). 1998. 48:195–200.
13. Schneider AB, Sarne DH. Long-term risks for thyroid cancer and other neoplasms after exposure to radiation. Nat Clin Pract Endocrinol Metab. 2005. 1:82–91.
14. Wermers RA, Khosla S, Atkinson EJ, Achenbach SJ, Oberg AL, Grant CS, Melton LJ 3rd. Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993-2001: an update on the changing epidemiology of the disease. J Bone Miner Res. 2006. 21:171–177.
15. Obara T, Fujimoto Y. Diagnosis and treatment of patients with parathyroid carcinoma: an update and review. World J Surg. 1991. 15:738–744.
16. Bondeson L, Sandelin K, Grimelius L. Histopathological variables and DNA cytometry in parathyroid carcinoma. Am J Surg Pathol. 1993. 17:820–829.
17. Lee PK, Jarosek SL, Virnig BA, Evasovich M, Tuttle TM. Trends in the incidence and treatment of parathyroid cancer in the United States. Cancer. 2007. 109:1736–1741.
18. Hoelting T, Weber T, Werner J, Herfarth C. Surgical treatment of parathyroid carcinoma (Review). Oncol Rep. 2001. 8:931–934.
19. Brasier AR, Nussbaum SR. Hungry bone syndrome: clinical and biochemical predictors of its occurrence after parathyroid surgery. Am J Med. 1988. 84:654–660.